Education
About Us
Working with TipRanks
Follow Us
Bioventus (BVS)
NASDAQ:BVS
BVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$5.28 - $14.38
Previous CloseN/A
Volume116.12K
Average Volume (3M)442.38K
Market Cap
$537.22M
Enterprise Value$737.31M
Total Cash (Recent Filing)$41.58M
Total Debt (Recent Filing)$335.63M
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Aug 12, 2025EPS Estimate
0.21Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.08
Shares Outstanding66,357,610
10 Day Avg. Volume619,924
30 Day Avg. Volume442,383
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)2.96
Price to Sales (P/S)0.00
P/FCF Ratio11.73
Enterprise Value/Market Cap1.37
Enterprise Value/Revenue0.34
Enterprise Value/Gross Profit1.90
Enterprise Value/Ebitda4.20
Forecast
1Y Price Target
$11.00Price Target Upside72.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
---
Bioventus News
PremiumCompany Announcements
Bioventus Reports Q1 2025 Financial Performance
PremiumCompany Announcements
Bioventus Earnings Call: Growth Amid Challenges
PremiumCompany Announcements
Bioventus Earnings Call: Strong Growth & 2025 Outlook---
Bulls Say, Bears Say
Bulls Say
Commercial ExecutionThe company is shifting from being a recovery story to an execution story, improving commercial execution across major business units.
Financial PerformanceBioventus posted a strong Q4, beating revenue, adjusted EBITDA, and pro forma EPS expectations with significant improvements in its business units.
Investment CapacityBioventus has financial breathing room to invest in commercial and R&D efforts, helping it remain competitive.
Bears Say
Debt ConcernsBioventus still has a significant amount of debt on its balance sheet, which could limit strategic uses of capital.
Pain TreatmentsPain Treatments growth benefited from a few million dollars of above-normal distributor orders, which is expected to negatively impact Q1 expectations as lower distributor orders are anticipated.
Revenue ChallengesQ1/H1 organic revenues should be more challenged given two fewer selling days in the Q1, pull-forward of HA orders from the Q1/25 to Q4/24, and continued BGS distributor choppiness for a couple more quarters.
---
Ownership Overview
31.86% Insiders
8.66% Mutual Funds
0.28% Other Institutional Investors
50.50% Public Companies and
Individual Investors
BVS FAQ
What was Bioventus’s price range in the past 12 months?
Bioventus lowest stock price was $5.28 and its highest was $14.38 in the past 12 months.
What is Bioventus’s market cap?
Bioventus’s market cap is $537.22M.
When is Bioventus’s upcoming earnings report date?
Bioventus’s upcoming earnings report date is Aug 12, 2025 which is in 88 days.
How were Bioventus’s earnings last quarter?
Bioventus released its earnings results on May 06, 2025. The company reported $0.08 earnings per share for the quarter, beating the consensus estimate of $0.025 by $0.055.
Is Bioventus overvalued?
According to Wall Street analysts Bioventus’s price is currently Undervalued.
Does Bioventus pay dividends?
Bioventus does not currently pay dividends.
What is Bioventus’s EPS estimate?
Bioventus’s EPS estimate is 0.21.
How many shares outstanding does Bioventus have?
Bioventus has 66,357,610 shares outstanding.
What happened to Bioventus’s price movement after its last earnings report?
Bioventus reported an EPS of $0.08 in its last earnings report, beating expectations of $0.025. Following the earnings report the stock price went down -11.807%.
Which hedge fund is a major shareholder of Bioventus?
Currently, no hedge funds are holding shares in BVS
---
Bioventus Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (72.41% Upside)
$11.00 (72.41% Upside)
Blogger Sentiment
Bullish
BVS Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 255.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
6.51%
12-Months-Change
Fundamentals
Return on Equity
-19.79%
Trailing 12-Months
Asset Growth
-12.95%
Trailing 12-Months
Company Description
Bioventus
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
---
BVS Company Deck
---
BVS Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted solid growth in certain segments such as Surgical Solutions and the expansion into the PRP market, along with increased EPS and reaffirmation of financial guidance. However, these positives were tempered by a decline in overall revenue, foreign currency losses, and challenges in the international segment.Read More>---
BVS Stock 12 Month Forecast
Average Price Target
$11.00
▲(72.41% Upside)
Technical Analysis
---